212 related articles for article (PubMed ID: 16958819)
41. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
42. Past-users of HRT are osteopenic four months after discontinuation:an observational and cross-sectional study.
Aubertin-Leheudre M; Mèlançon MO; Chaput JP; Dionne IJ
J Women Aging; 2006; 18(4):19-29. PubMed ID: 17200061
[TBL] [Abstract][Full Text] [Related]
43. Prevention of osteoporotic fractures in post-menopausal women.
Compston J
Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Jun; 14(2):251-64. PubMed ID: 11035905
[TBL] [Abstract][Full Text] [Related]
44. A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women.
Heikkinen J; Vaheri R; Haapalahti J; Timonen U
Menopause Int; 2008 Jun; 14(2):70-7. PubMed ID: 18519268
[TBL] [Abstract][Full Text] [Related]
45. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D
Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532
[TBL] [Abstract][Full Text] [Related]
46. Fracture risk and bone density of peri- and early postmenopausal women with uterine leiomyomas.
Randell KM; Honkanen RJ; Tuppurainen MT; Kröger H; Jurvelin JS; Saarikoski S
Maturitas; 2006 Feb; 53(3):333-42. PubMed ID: 16019169
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
[TBL] [Abstract][Full Text] [Related]
48. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
49. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus.
Safaei H; Janghorbani M; Aminorroaya A; Amini M
Acta Diabetol; 2007 Jun; 44(2):76-82. PubMed ID: 17530471
[TBL] [Abstract][Full Text] [Related]
50. Initiation of osteoporosis treatment after bone mineral density testing.
Pressman A; Forsyth B; Ettinger B; Tosteson AN
Osteoporos Int; 2001; 12(5):337-42. PubMed ID: 11444079
[TBL] [Abstract][Full Text] [Related]
51. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
52. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
53. Longitudinal evaluation of serum leptin and bone mineral density in early postmenopausal women.
Di Carlo C; Tommaselli GA; Di Spiezio Sardo A; Sammartino A; Attianese W; Gargano V; Bifulco G; Nappi C
Menopause; 2007; 14(3 Pt 1):450-4. PubMed ID: 17242633
[TBL] [Abstract][Full Text] [Related]
54. Effect of raloxifene on lowering lipid parameters in patients with osteoporosis.
Miskić B; Bistrović D; Cosić V; Leko N; Balen-Jandrić M; Balen I; Samardzić P; Miskić D
Int J Clin Pharmacol Res; 2003; 23(4):107-10. PubMed ID: 15224499
[TBL] [Abstract][Full Text] [Related]
55. Effects of raloxifene on changes in bone density.
Miskić B; Bistrović D; Vizner B; Cosić V; Miskić D; Herman D
Coll Antropol; 2006 Dec; 30(4):767-70. PubMed ID: 17243547
[TBL] [Abstract][Full Text] [Related]
56. Related factors in bone mineral density of lumbal and femur in natural postmenopausal women.
Hassa H; Tanir HM; Senses T; Oge T; Sahin-Mutlu F
Arch Gynecol Obstet; 2005 Dec; 273(2):86-9. PubMed ID: 16001199
[TBL] [Abstract][Full Text] [Related]
57. [Effects of long-term and low-dose hormone replacement therapy on bone mineral density in postmenopausal women].
Nie M; Sun ML; Ge QS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):421-4. PubMed ID: 16900649
[TBL] [Abstract][Full Text] [Related]
58. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
59. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
60. Impact of menopause on lipid and bone metabolism and effect of hormone replacement therapy.
Murano T; Izumi S; Kika G; Haque SF; Okuwaki S; Mori A; Suzuki T; Matsubayashi H; Ikeda M; Goya K; Makino T
Tokai J Exp Clin Med; 2003 Oct; 28(3):109-19. PubMed ID: 15055403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
